Abstract: A device for centering and guiding a shaft of an aircraft turbine engines. The device includes an outer ring of a rolling bearing, the ring extending about a main axis and having orifices arranged around the axis; an annular bearing support extending about the main axis and at least partially about the ring, the support having orifices and openings arranged about the axis; and a series of studs for linking the ring to the support, the studs being distributed about the main axis and having elongation axes substantially parallel to the main axis, the body of each of the studs passing through one of the openings. Some of the studs, have bodies that pass with a first positive clearance and a second virtually zero clearance through the first openings, the first and second clearances being configured so that the device has different displacement amplitudes.

Abstract: A device for centering and guiding a shaft of an aircraft turbine engine, the device including an outer ring of a rolling bearing, the ring extending about an axis; an annular bearing support extending about the axis and at least partially about the ring; at least one series of connecting elements for linking the ring to the support, the connecting elements being interposed between an inner cylindrical rim of the ring and an outer cylindrical rim of the support that extends about the inner rim, and each having a first radially outer end for linking to the outer cylindrical rim and a second radially inner end for linking to the inner cylindrical rim, the ring, the support and the connecting elements being integrally formed, the connecting elements being enclosed in an annular housing that is radially delimited by the rims and laterally enclosed by an annular web.

Abstract: A device for centering and guiding a shaft of an aircraft turbine engine is provided. The device includes an outer ring of a rolling bearing extending about an axis and having orifices, an annular bearing support extending about the axis and at least partially about the ring, the support having orifices and a series of studs for connecting the ring to the support. The studs can be distributed about the axis and extend parallel to the axis. The ends of first studs can be engaged without clearance in the orifices, and ends of second studs can be engaged with clearances in the orifices of the ring and/or of the support, the clearances being configured so that the device has different stiffnesses in at least two directions perpendicular to the axis.

Abstract: Devices, systems, and techniques for therapy delivery and healthcare management is described. In one example, a system comprises a delivery device configured to execute therapy information comprising a treatment schedule specifying one or more treatments over a time period, wherein for each of the one or more treatments, the therapy information comprises a treatment type and a treatment amount; and processing circuitry configured to: determine a modification to the therapy information based on a recommendation of a digital twin, wherein the digital twin determines an estimated glucose level expected to be within a healthy range if the delivery device executes the modification to therapy information; and in response to physician review of the modification to the therapy information, output, to a healthcare provider system for the patient, data indicating completion of a healthcare service corresponding to the physician review.

Abstract: Various techniques facilitate the development of an image library that can be used to train and/or validate an automated visual inspection (AVI) model, such an AVI neural network for image classification. In one aspect, an arithmetic transposition algorithm is used to generate synthetic images from original images by transposing features (e.g., defects) onto the original images, with pixel-level realism. In other aspects, digital inpainting techniques are used to generate realistic synthetic images from original images. Deep learning-based inpainting techniques may be used to add, remove, and/or modify defects or other depicted features. In still other aspects, quality control techniques are used to assess the suitability of image libraries for training and/or validation of AVI models, and/or to assess whether individual images are suitable for inclusion in such libraries.

Abstract: A hybrid display may include different display portions with different resolutions. The high resolution display portion may be positioned in a main viewing area for the viewer whereas the low resolution display portion may be positioned in a peripheral viewing area. The high resolution display portion may have a silicon backplane. The low resolution display portion may have a different type of backplane such as a thin-film transistor backplane. The different display portions may optionally share a common organic light-emitting diode layer such that light is emitted from the same plane across both display portions. The high resolution display portion may emit light through a transparent window in the low resolution display portion. A high resolution display may also be formed by separately forming a frontplane and a backplane. Conductive attachment structures such as indium bumps may be used to mechanically and electrically connect the backplane to the frontplane.

Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

Abstract: Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

Abstract: The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject.

Abstract: The present invention relates to a method of identifying a patient suffering from cancer as benefiting or not benefiting from immune checkpoint inhibition therapy comprising the steps of measuring an expression level of one or more preselected markers in a cancerous biological sample obtained from the patient, identifying a differentially expressed alternative promoter based on the expression level of the one or more preselected markers, calculating an alternative promoter usage score and identifying the patient as benefiting or not benefiting from immune checkpoint inhibition therapy using the alternative promoter usage score. The present invention also relates to a biomarker for excluding a patient suffering from cancer from immune checkpoint inhibition therapy.

Abstract: The present invention relates to a method for determining the presence or absence of at least one promoter in a cancerous biological sample relative to a non-cancerous biological sample. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method for modulating the activity of at least one cancer-associated promoter in a cell, a method for modulating the immune response of a subject to cancer, a method for determining the presence of at least one cancer-associated promoter in a cancerous biological sample relative to a non-cancerous biological sample and a biomarker for detecting cancer in a subject.

Abstract: Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: The present disclosure is a method comprising the steps of performing one or more nucleic-acid based assays to identify mutations present in the breast tissue acquired from the subject corresponding to a first test module and a second test module associated with detection of at least one predetermined mutation of one or more genes, wherein each test module is configured to provide a positive outcome corresponding to at least one predetermined mutation detected in the tissue or a negative outcome corresponding to absence of detectable predetermined mutation in the sample; and identifying the type of neoplasm of the breast tissue based upon the provided outcome of the both test modules. Preferably, the first test module is associated with detection of mutation in MED12 gene and/or RARA gene, while the second test module is associated with detection of mutation in FLNA gene, SETD2 gene and/or MLL2 gene.

Abstract: Technology described herein includes an arrangement whereby a hardware-based solution is implemented to enable mirroring of NVRAM data in a master server directly to NVRAM in a sleeper server. Both the master server and sleeper server implement a like motherboard unit, which is configured to implement the mirroring technology. That is, the roles of master and sleeper may be reversed. The master server includes a hardware module that monitors (but does not affect) NVRAM operations at the master server, and replicates those operations via a high speed communications link, such as a fiber optic link, to the sleeper server. The term “high speed communications link” refers to a link with at least 2.5 gigabit speed, and preferably at least 5 gigabit speed. The sleeper server is configured to, when in sleeper mode, suspend control of its own NVRAM module. Instead, the NVRAM module is controlled by a module that is configured to receive NVRAM operations via the fiber optic link, and apply those operations.

Abstract: The present invention relates to a method for determining or making of a prognosis if a patient has cancer or is at an increased risk of having cancer, the method comprising testing for the presence of one or more cancer-associated fusion genes, or proteins derived thereof, in a sample obtained from a patient. More specifically, the present invention relates to fusion genes CLEC16A-EMP2, SNX2-PRDM6, MLL3-PRKAG2, DUS2L-PSKH1 and CLDN18-ARHGAP26 in gastric cancer. Use of the method and a kit when used in the method are also provided.

Abstract: The present invention is directed to methods for determining the activity of a promoter. The present invention further describes a method for determining the susceptibility of a subject to cancer and biomarkers for detecting cancer in a subject.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.